US 12,226,411 B2
Soluble guanylate cyclase activators for treating portal hypertension
Judith Maria Ertle, Ingelheim am Rhein (DE); Jochen Huber, Mittelbiberach (DE); and Leo John Seman, Cheshire, CT (US)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Mar. 20, 2023, as Appl. No. 18/123,359.
Claims priority of provisional application 63/321,780, filed on Mar. 21, 2022.
Prior Publication US 2023/0293513 A1, Sep. 21, 2023
Int. Cl. A61K 31/4709 (2006.01); A61K 31/351 (2006.01); A61P 1/16 (2006.01)
CPC A61K 31/4709 (2013.01) [A61K 31/351 (2013.01); A61P 1/16 (2018.01)] 13 Claims
 
1. A method for treating a patient with compensated cirrhosis, comprising administering to the patient a therapeutically effective amount of a soluble guanylate cyclase (sGC) activator of formula (I),

OG Complex Work Unit Chemistry
wherein:
A is a 5-7 membered saturated heterocyclyl group containing one nitrogen and optionally one oxygen, wherein one carbon of said heterocyclyl group is optionally substituted with one or two groups selected from C1-3alkyl and oxo ;
R1 is C1-4 alkyl optionally substituted with a methoxy group;
R2 is selected from H, F, Cl, C1-3alkyl, —CN, —OMe and —CF3;
R3 is selected from H and —CH3;
R4 is selected from H, F, —CH3 and —OMe;
R5 is selected from H, Cl, —CH3, —CH2CH3, —CF3, F, and —OMe;
R6 is bonded to the nitrogen on A and is selected from H, C1-6alkyl, —(CH2)nC3-6cycloalkyl, —C(O)C1-6alkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl, and —(CH2)n-heteroaryl, —SO2aryl, SO2C1-6alkyl wherein said C1-6alkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl and —(CH2)n-heteroaryl are optionally substituted with one to four groups independently selected from C1-3alkyl, halogen, C1-3alkoxy, —CF3, —OH, oxo, —(CH2)1-3O(CH2)2-3OH, and —SO2CH3;
R7 is selected from H, —CH3, —CH2CH3, —CF3, F, and —CN;
n is 0, 1 or 2;
or a pharmaceutically acceptable salt thereof.